{
    "2020-08-27": [
        [
            {
                "time": "2023-10-18",
                "original_text": "New England Journal of Medicine Publishes Phase 1/2 Data for Retevmoâ„¢ (selpercatinib) in Advanced RET-Driven Lung and Thyroid Cancers",
                "features": {
                    "keywords": [
                        "Phase 1/2 Data",
                        "Retevmo",
                        "selpercatinib",
                        "RET-Driven",
                        "Lung Cancer",
                        "Thyroid Cancer"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}